GENETIC ANALYSIS NK -60 Cash Flow Reinvestment Rate

Latest as of December 2025: 0.17x

GENETIC ANALYSIS NK -60 cash flow reinvestment rate. GENETIC ANALYSIS NK -60 (8V8) has a Cash Flow Reinvestment Rate of 0.17x as of December 2025, reinvesting €1.36 Million (capex €1.36 Million ) from operating cash flow of €8.04 Million. Explore 8V8 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.17x

(Capex + Investments) / Operating CF

Total Reinvested

€1.36 Million

Capex + Investments

Operating Cash Flow

€8.04 Million

EUR

Capital Expenditures

€1.36 Million

EUR

Cash Flow Reinvestment Rate of GENETIC ANALYSIS NK -60 (2025–2025)

Cash flow reinvestment rate of GENETIC ANALYSIS NK -60 from 2025 to 2025. Historical reinvestment intensity for GENETIC ANALYSIS NK -60 across 1 annual periods. Explore GENETIC ANALYSIS NK -60 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

GENETIC ANALYSIS NK -60 Cash Flow Reinvestment Rate by Year (2025–2025)

GENETIC ANALYSIS NK -60 cash flow reinvestment rate by year from 2025 to 2025. Year-by-year capital reinvestment analysis for GENETIC ANALYSIS NK -60. For the full cash flow conversion analysis, see how efficiently does GENETIC ANALYSIS NK -60 generate cash.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2025	2.31x	€5.54 Million	€2.40 Million	€5.54 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow